The potential predictive role of KRAS, a gene coding for an oncoprotein that acts upstream of CDK4/6 by modulating cyclin D1 overexpression [3], has also been analyzed for CDK4/6 inhibitor resistance in patients with metastatic BC. Here, KRAS is linked to breast cancer.